iCAD Announces AERB Approval of Xoft System in India

A global medical technology leader providing innovative cancer detection and therapy solutions, announced today that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® has received an Atomic Energy Regulatory Board (AERB) Type Approval for use in India. The approval affirms that the system conforms to established safety standards and makes the full suite of the Company’s electronic brachytherapy products available to clinicians and patients across the country. The Omega Hospitals – Hyderabad, part of the Hyderabad Institute of Oncology, is the first site to adopt the Xoft System in India. Omega Hospitals is a world-class, integrated healthcare delivery system providing more than 89,500 patient care visits annually.
“AERB approval of the Xoft System represents an important milestone in our continued efforts to provide healthcare facilities worldwide with leading-edge technology offering clinically-proven treatment options for a range of cancers,” said Ken Ferry, CEO of iCAD. “We are pleased to join with the Omega Hospitals to provide unprecedented access to this advanced therapy to patients in India, where cancer cases are significantly increasing. We look forward to partnering with additional providers to deliver electronic brachytherapy on a broader scale throughout the country.”
Omega Hospitals – Hyderabad will be utilizing the Xoft System for the treatment of early-stage breast cancer and gynecological cancers. The Xoft System is FDA cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. The system utilizes a proprietary, miniaturized x-ray source to deliver precise radiation treatment directly to a cancerous area while sparing surrounding healthy tissue. The system requires only minimal shielding and therefore does not require construction investment.
“At Omega Hospitals, we strive to provide patients with state-of-the-art treatment options and unparalleled medical expertise, resulting in outstanding patient care,” said Dr. Ch. Mohana Vamsy, Chief Surgical Oncologist at Omega Hospitals. “The Xoft System offers a uniquely valuable solution to eradicate an array of cancers, equipping us with cutting-edge technology that strongly aligns with our mission to deliver positive patient outcomes. We are pleased to partner with iCAD to offer electronic brachytherapy with the Xoft System to patients in India.”
Source:https://markets.businessinsider.com/news/stocks/icad-announces-aerb-approval-of-xoft-system-in-india-1027493298

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more